Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Reminder: Today is the deadline for Shareholder Meeting attendees to send their RSVP to Diane:
2014 Elite Pharmaceuticals Annual Meeting of Shareholders
WHERE:
Residence Inn by Marriott
206 Route 303
Orangeburg, NY 10962
WHEN:
Wednesday, May 21, 2014
10:30 a.m. EDT
ELTP Investor Relation's Diane Will would like for those who plan to attend the ELTP Annual Shareholder's to RSVP her (Phone: 518-398-6222 or e-mail: dianne@elitepharma.com). Diane needs attendee responses/count by May 19th so she can make arrangements for adequate meeting room and meal accommodations Those who indicated on Proxyvote.com their intention to attend the meeting should also send an RSVP to Diane.
If you have questions regarding today's news, please add to the list for the Shareholder meeting. I am planning to send the list to ELTP this afternoon.
***** Elite Pharmaceuticals Shareholder Meeting Questions *****
(Copy/paste and add your question(s) at the end of the latest posted list - Submission deadline - May 19th @ 12:00PM)
1a. Status update on the clinical trials?
b. When can we expect Lifetree abuse liability results?
c. How long do you expect these trials to last?
d. How many products are tested at a time in these studies?
e. Is the plan is to file upon successful results?
2. Any developments/updates in partnership discussions?
3. Are there plans to enhance ELTP's website? The current one appears visually "dated".
4a. How many ART drugs can ELTP get to market without a partner?
b. In the absence of being acquired, which eliminates the strategic growth concerns, the fact remains that,
with no existing infrastructure to support the supply chain necessary for success, the choices for Elite are
three-fold: a) spend to create the supporting infrastructure; b) acquire it through a merger or acquisition
of a firm with the existing infrastructure; or c) create a partnership with a larger company possessing the
needed capabilities. While differing strategic scenarios, in your estimation which path offers Elite the best
chance for success and why?
6. Is ELTP still on schedule for at least ONE ART/ADT opiod FDA submission in 2014? How many are planned for 2015?
7. Any plans to present at upcoming conferences again like in September 2013?
8. Is the plan to attempt to market the first drug(s) ourselves by hiring a sales team or partner for sales/marketing?
9a. Does ELTP management stand by the valuation stated in the February conference call?
b. What is the name of the firm that completed the valuation and, given the events of the past three months,
why are you confident the valuation remains accurate?
10. Is a reverse split still a possibility in the $1 range as stated in the February conference call? Why reverse split before allowing ELTP to organically grow to the value stated?
11. How will the additional 400 mil+ shares effect the share price? Were these additional shares considered when the independent analysis was done months ago?
12. Is ELTP still active in "moneytizing"? their Novel stake? In my opinion, Novel can pay for at least 5 or 6 ART products without further dilution and so use this dilution to expand the company true merger or buyout
13.
14.
Mistakenly typed the wrong deadine date in my earlier post:
***** Elite Pharmaceuticals Shareholder Meeting Questions *****
(Copy/paste and add your question(s) at the end of the latest posted list - Submission deadline - May 19th @ 12:00PM)
1a. Status update on the clinical trials?
b. When can we expect Lifetree abuse liability results?
c. How long do you expect these trials to last?
d. How many products are tested at a time in these studies?
e. Is the plan is to file upon successful results?
2. Any developments/updates in partnership discussions?
3. Are there plans to enhance ELTP's website? The current one appears visually "dated".
4a. How many ART drugs can ELTP get to market without a partner?
b. In the absence of being acquired, which eliminates the strategic growth concerns, the fact remains that,
with no existing infrastructure to support the supply chain necessary for success, the choices for Elite are
three-fold: a) spend to create the supporting infrastructure; b) acquire it through a merger or acquisition
of a firm with the existing infrastructure; or c) create a partnership with a larger company possessing the
needed capabilities. While differing strategic scenarios, in your estimation which path offers Elite the best
chance for success and why?
6. Is ELTP still on schedule for at least ONE ART/ADT opiod FDA submission in 2014? How many are planned for 2015?
7. Any plans to present at upcoming conferences again like in September 2013?
8. Is the plan to attempt to market the first drug(s) ourselves by hiring a sales team or partner for sales/marketing?
9a. Does ELTP management stand by the valuation stated in the February conference call?
b. What is the name of the firm that completed the valuation and, given the events of the past three months,
why are you confident the valuation remains accurate?
10. Is a reverse split still a possibility in the $1 range as stated in the February conference call? Why reverse split before allowing ELTP to organically grow to the value stated?
11. How will the additional 400 mil+ shares effect the share price? Were these additional shares considered when the independent analysis was done months ago?
12. Is ELTP still active in "moneytizing"? their Novel stake? In my opinion, Novel can pay for at least 5 or 6 ART products without further dilution and so use this dilution to expand the company true merger or buyout
13.
14.
***** Elite Pharmaceuticals Shareholder Meeting Questions *****
(Copy/paste and add your question(s) at the end of the latest posted list - Submission deadline - May 18th @ 12:00PM)
1a. Status update on the clinical trials?
b. When can we expect Lifetree abuse liability results?
c. How long do you expect these trials to last?
d. How many products are tested at a time in these studies?
e. Is the plan is to file upon successful results?
2. Any developments/updates in partnership discussions?
3. Are there plans to enhance ELTP's website? The current one appears visually "dated".
4a. How many ART drugs can ELTP get to market without a partner?
b. In the absence of being acquired, which eliminates the strategic growth concerns, the fact remains that,
with no existing infrastructure to support the supply chain necessary for success, the choices for Elite are
three-fold: a) spend to create the supporting infrastructure; b) acquire it through a merger or acquisition
of a firm with the existing infrastructure; or c) create a partnership with a larger company possessing the
needed capabilities. While differing strategic scenarios, in your estimation which path offers Elite the best
chance for success and why?
6. Is ELTP still on schedule for at least ONE ART/ADT opiod FDA submission in 2014? How many are planned for 2015?
7. Any plans to present at upcoming conferences again like in September 2013?
8. Is the plan to attempt to market the first drug(s) ourselves by hiring a sales team or partner for sales/marketing?
9a. Does ELTP management stand by the valuation stated in the February conference call?
b. What is the name of the firm that completed the valuation and, given the events of the past three months,
why are you confident the valuation remains accurate?
10. Is a reverse split still a possibility in the $1 range as stated in the February conference call? Why reverse split before allowing ELTP to organically grow to the value stated?
11. How will the additional 400 mil+ shares effect the share price? Were these additional shares considered when the independent analysis was done months ago?
12. Is ELTP still active in "moneytizing"? their Novel stake? In my opinion, Novel can pay for at least 5 or 6 ART products without further dilution and so use this dilution to expand the company true merger or buyout
13.
14.
no2koolaid,
I'll add your questions to the list...
Regarding the timing of when it's best to present questions to ELTP... It really doesn't matter since postings on IHub are wide-open for anyone to see anyway.
MJ
Dr. Pete,
I look at it this way... If I didn't have trust/faith in ELTP management to look out for the best interest of its shareholders... Let alone provide truthful/honest answers to the shareholder questions... I wouldn't be invested in ELTP in the first place.
MJ
no2koolaid,
Thanks for your comments... Though I can only claim ownership to questions 1 & 2 from the list. I'm just trying to facilitate the collection of questions from other shareholders.
I appreciate your input... But I'm hesitant to make changes other than minor grammatical/editorial adjustments to posted questions that aren't mine. Suggest that you compose your questions and add them to the list. If they are related to the topic of an existing question, it might be of benefit to insert your's right after the applicable question to keep the subject matter consolidated/organized... Such as Question# 4A followed by 4B.
I was planning to send the final list to Diana Monday morning to give them some time to prepare their responses.
MJ
***** Elite Pharmaceuticals Shareholder Meeting Questions *****
(Copy/paste and add your question(s) at the end of the latest posted list)
1. Status update on the clinical trials?
2. Any developments/updates in partnership discussions?
3. Are there plans to enhance ELTP's website? The current one appears visually "dated".
4. How many ART drugs can ELTP get to market without a partner?
5. When can we expect Lifetree abuse liability results? How long do you expect these trials to last? How many products are tested at a time in these studies? Is the plan is to file upon successful results?
6. Is ELTP still on schedule for at least ONE ART/ADT opiod FDA submission in 2014? How many are planned for 2015?
7. Any plans to present at upcoming conferences again like in September 2013?
8. Is the plan to attempt to market the first drug(s) ourselves by hiring a sales team or partner for sales/marketing?
9. Does ELTP management stand by the valuation stated in the February conference call?
10. Is a reverse split still a possibility in the $1 range as stated in the February conference call? Why reverse split before allowing ELTP to organically grow to the value stated?
11.
12.
Hike,
I plan to attend the shareholder meeting, as well, and can submit the questions to ELTP management. I will take notes at the meeting and will post question/answers here on IHub when I get back home Wednesday evening. I probably could use some editorial assistance from my fellow shareholders who also attend the meeting to make sure what I capture is correct/complete.
MJ
***** Elite Pharmaceuticals Shareholder Meeting Questions *****
(Copy/paste and add your question(s) at the end of the latest posted list)
1. Status update on the clinical trials?
2. Any developments in partnership discussions?
3. Are there plans to enhance our website? Our current one appears visually "dated".
4. How many ART drugs can we get to market without a partner?
5. When can we expect Lifetree abuse liability results?
6. Are we still on schedule for at least ONE ART/ADT opiod FDA submission in 2014, and how many for 2015?
7.
8.
9.
10.
It's #1 on the list to ask at the shareholder's meeting.
If there are other questions, just copy/paste and add your question(s) at the end of the latest posted list:
***** Elite Pharmaceuticals Shareholder Meeting Questions *****
1. Status update on the clinical trials?
2. Any developments in partnership discussions?
3.
4.
5.
6.
I plan to attend next week's shareholder meeting. Suggest that we submit a consolidated list of questions to ELTP management for discussion at the meeting. Let's build a single list by copying/pasting and adding your question(s) at the end of the latest posted list. I'll kick-off the list with a couple items:
***** Elite Pharmaceuticals Shareholder Meeting Questions *****
1. Status update on the clinical trials?
2. Any developments in partnership discussions?
3.
4.
5.
6.
E-mail sent out by ELTP's Investor Relations Diane Will:
Subject: RSVP for Elite's Annual Shareholder Meeting
Elite's Annual Meeting is one week away!
Elite's annual meeting is scheduled for next Wednesday, May 21st at 10:30 AM.
If you were a shareholder as of March 28th, the record date for this meeting, and you plan to attend, please let me know at your earliest convenience if you have not already done so.
2014 Elite Pharmaceuticals Annual Meeting of Shareholders
WHERE: Residence Inn by Marriott
206 Route 303
Orangeburg, NY 10962
WHEN: Wednesday, May 21, 2014
10:30 a.m. EDT
We hope to see you at the meeting !
Contact:
Elite Pharmaceuticals, Inc.
Dianne Will, Investor Relations, 518-398-6222
Dianne@elitepharma.com
***Reminder***
Attendee's RSVP deadline for the May 21st Shareholder's meeting is next Monday:
2014 Elite Pharmaceuticals Annual Meeting of Shareholders
WHERE:
Residence Inn by Marriott
206 Route 303
Orangeburg, NY 10962
WHEN:
Wednesday, May 21, 2014
10:30 a.m. EDT
ELTP Investor Relation's Diane Will would like for those who plan to attend the ELTP Annual Shareholder's to RSVP her (Phone: 518-398-6222 or e-mail: dianne@elitepharma.com). Diane needs attendee responses/count by May 19th so she can make arrangements for adequate meeting room and meal accommodations. Those who indicated on Proxyvote.com their intention to attend the meeting should also send an RSVP to Diane.
Why I still have my Harcourt baseball cap in brand new condition. Was that the Florida shareholder's meeting we got those??? Wonder what I could get for it on eBay. 500K shares of HRCT stock? LOL
I wanna go!...
MJ
Don't know about a conference call... But there's a Shareholder's meeting on May 21st:
2014 Elite Pharmaceuticals Annual Meeting of Shareholders
WHERE:
Residence Inn by Marriott
206 Route 303
Orangeburg, NY 10962
WHEN:
Wednesday, May 21, 2014
10:30 a.m. EDT
ELTP Investor Relation's Diane Will would like for those who plan to attend the ELTP Annual Shareholder's to RSVP her (Phone: 518-398-6222 or e-mail: dianne@elitepharma.com). Diane needs attendee responses/count by May 19th so she can make arrangements for adequate meeting room and meal accommodations Those who indicated on Proxyvote.com their intention to attend the meeting should also send an RSVP to Diane.
I know that ELTP is providing continental breakfast and lunch for attendees at the shareholder's meeting... A share price North of a $1 by May 21st might just also include champagne! Heck, I'd spring for a round of drinks on me if that were to happen.
The meeting location changed when it was realized more people were coming than had in the past. So a larger venue was needed.
Reminder:
2014 Elite Pharmaceuticals Annual Meeting of Shareholders
WHERE:
Residence Inn by Marriott
206 Route 303
Orangeburg, NY 10962
WHEN:
Wednesday, May 21, 2014
10:30 a.m. EDT
ELTP Investor Relation's Diane Will would like for those who plan to attend the ELTP Annual Shareholder's to RSVP her (Phone: 518-398-6222 or e-mail: dianne@elitepharma.com). Diane needs attendee responses/count by May 19th so she can make arrangements for adequate meeting room and meal accommodations Those who indicated on Proxyvote.com their intention to attend the meeting should also send an RSVP to Diane.
Go ahead and add me to the list of so-called "dumb" investors for not selling a single ELTP share. The truth about who is smart or dumb will be told by ELTP's shareprice in a year or two. I believe that Couch, myself and our fellow long shareholders will show to be the Einsteins of this Board.
Reminder:
Diane would like attendee RSVPs by May 19th:
2014 Elite Pharmaceuticals Annual Meeting of Shareholders
WHERE: Residence Inn by Marriott
206 Route 303
Orangeburg, NY 10962
WHEN: Wednesday, May 21, 2014
10:30 a.m. EDT
RSVP: Dianne Will at 518-398-6222 or dianne@elitepharma.com (not mandatory, but helpful for planning purposes if you plan to attend)
Dianne Will from ELTP IR just e-mailed me:
"I also noticed on Proxyvote.com that you could indicate if you planned to attend the meeting, but I have never seen any feedback from them."
So I would recommend that the folks who indicated they were going to attend the shareholder's meeting on Proxyvote.com, also send an RSVP to Diane (dianne@elitepharma.com)
Nope.... Just breakfast and lunch.
Diane would like attendee RSVPs by May 19th:
2014 Elite Pharmaceuticals Annual Meeting of Shareholders
WHERE: Residence Inn by Marriott
206 Route 303
Orangeburg, NY 10962
WHEN: Wednesday, May 21, 2014
10:30 a.m. EDT
RSVP: Dianne Will at 518-398-6222 or dianne@elitepharma.com (not mandatory, but helpful for planning purposes if you plan to attend)
ELTP's Investor Relations, Dianne Will, is asking shareholders to let her know (e-mail: dianne@elitepharma.com) if they are going to attend the annual shareholder's meeting. Dianne needs attendee responses/count by May 19th so she can make arrangements for adequate meeting room and lunch accommodations.
I plan to go and look forward to meeting Nasrat Hakim and the rest of the ELTP team, not to mention, my fellow shareholders. I hope to see you there!
MJ
Ditto here... Voted yes on all proxy items.
Here's an even better, more applicable link to learn how market manipulation schemes work by Stock Bashing: "This scheme is usually orchestrated by savvy online message board posters (a.k.a. "Bashers") who make up false and/or misleading information about the target company in an attempt to get shares for a cheaper price. This activity, in most cases, is conducted by posting libelous posts on multiple public forums.
http://en.wikipedia.org/wiki/Market_manipulation
WASHINGTON (AP) — U.S. Sen. Joe Manchin is calling on the government's top health official to overturn the approval of a powerful painkiller, arguing that the pill Zohydro could add to the national epidemic of prescription drug abuse.
The West Virginia Democrat joins a chorus of lawmakers, state prosecutors and medical groups seeking a reversal of the Food and Drug Administration's October approval. In a letter Monday, Manchin asks Health and Human Services Secretary Kathleen Sebelius to overrule the agency's decision.
Zohydro is the first single-ingredient hydrocodone drug ever cleared for U.S. patients. The extended-release pill contains more of the narcotic pain reliever than older combination pills, such as Vicodin.
The FDA approval surprised many doctors, since the agency's own advisers voted overwhelmingly against the drug, citing its abuse potential.
You know what's kinda ironic?... If ELTP's pps had made a slow and steady climb (up a penny or two each day) to $.67 instead of rocketing to almost $1 and then dropping back down to the same $.67... There would be euphoria, glad handing and back slapping on this board...Instead of the current back biting. Interesting how the same pps yields doom and gloom. ELTP's potential hasn't changed... Isn't all this rancor the past couple of days gonna look rather silly when news of the patent, trial results and/or partnership is released and ELTP breaks through the $1 barrier and beyond?. I think so... IMHO
Not a problem... ELTP = "barrel of money" IMHO
Couch - I'm a more of an old school British sports car type... If I score big with ELTP, I'd be looking to buy myself either a mid-60's Morgan +4, Jaguar E Type, Austin Healey 3000 or Lotus Elan. Heck, the future prospects look so bright for ELTP... Maybe I can get them all, plus build a garage to keep them in.
Still climbing back up now @ $.74 on +12 million volume.
Climbing back up.... $.7350 Steady as she goes, Captain!
You're not alone... Lots of lurkers here, including me. Hang in there.
Just broke through 7 million in volume... Half way there!!!
ELTP passed the 6 million volume mark in just 1 1/2 hours of trading. At this rate, ELTP should surpass yesterday's 14 million.
$.20 pp with 3,252,950 Volume!!!
I'd be interested in hearing what others are planning to do and their rationale... TIA
ELTP is #8 on the most active Investorshub boards!!! To dah moon!!!